EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Predicting immune‐related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study

Cecilia Olsson Ladjevardi iD, Anthoula Koliadi, Viktoria Rydén, Ali Inan El-Naggar, Evangelos Digkas, Antonios Valachis iD, Gustav J Ullenhag

Cancer Medicine · 2023

DOI: 10.1002/cam4.6013 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Cancer Medicine, 2023. Verfasst von Cecilia Olsson Ladjevardi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Frailty, Immune Checkpoint Inhibitors, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Checkpoint inhibitors (CPIs) are in widespread clinical use. Little is known about which patients are at risk for developing toxicity. It is essential being able to identify patients with higher risk of experiencing immune‐related adverse events (IRAEs) before initiation of CPI treatment to optimize treatment decisions and follow‐up strategy. The aim of this study was to investigate whether a simplified frailty score based on performance status (PS), age, and comorbidity expressed as Charlson comorbidity index (CCI) could predict development of IRAEs.

Methods

We performed a retrospective cohort study at three Swedish centers. All patients ( n = 596) treated with PD‐L1 or PD‐1 inhibitor for advanced cancer between January 2017 and December 2021 were included.

Results

In total, 361 patients (60.6%) were classified as nonfrail and 235 (39.4%) as frail. The most common cancer type was non‐small cell lung cancer ( n = 203; 34.1%) followed by malignant melanoma ( n = 195; 32.7%). Any grade of IRAE occurred in 138 (58.7%) frail and in 155 (42.9%) non‐frail patients (OR: 1.58; 95% CI: 1.09–2.28). Age, CCI, and PS did not independently predict the occurrence of IRAEs. Multiple IRAEs occurred in 53 (22.6%) frail and in 45 (12.5%) nonfrail patients (OR: 1.62; 95% CI: 1.00–2.64).

Discussion

In conclusion, the simplified frailty score predicted all grade IRAEs and multiple IRAEs in multivariate analyses whereas age, CCI, or PS did not separately predict development of IRAEs suggesting that this easy‐to‐use score may be of value in clinical decision making but a large prospective study is needed to assess its true value.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FrailtyImmune Checkpoint InhibitorsCarcinoma, Non-Small-Cell LungLung NeoplasmsMelanomaSkin NeoplasmsRetrospective StudiesHumansSwedenAgedAged, 80 and overYoung AdultAdultMiddle AgedMaleFemale

Stichwörter der Autor:innen

advanced cancercheckpoint inhibitorcohort studyfrailty scoreimmune-related adverse events

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.
  • Department of Oncology, Uppsala University Hospital, Uppsala, Sweden.
  • Department of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
  • Department of Oncology, Mälarsjukhuset, Eskilstuna, Sweden.

ORCID-Profile: Cecilia Olsson Ladjevardi, Antonios Valachis

Zitieren

APA

Olsson Ladjevardi, C., Koliadi, A., Rydén, V., Inan El-Naggar, A., Digkas, E., Valachis, A., & Ullenhag, G. J. (2023). Predicting immune‐related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study. Cancer Medicine. https://doi.org/10.1002/cam4.6013

Vancouver

Olsson Ladjevardi C, Koliadi A, Rydén V, Inan El-Naggar A, Digkas E, Valachis A, et al. Predicting immune‐related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study. Cancer Medicine. 2023. doi:10.1002/cam4.6013

BibTeX
@article{OlssonLadjevardi2023,
  author = {Olsson Ladjevardi, Cecilia and Koliadi, Anthoula and Rydén, Viktoria and Inan El-Naggar, Ali and Digkas, Evangelos and Valachis, Antonios and Ullenhag, Gustav J},
  title = {Predicting immune‐related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.6013}
}
Kostenlos starten →